Xintela licenses human antibody technology for cancer therapyXintela AB (publ) today announced the company has licensed antibody technology for the development of human antibodies in diagnostics and therapy. The antibodies, directed to Xintela's markers integrin 101 och integrin 111, are already adapted for human use. This means that Xintela saves both time and money and that Xintela's cancer products can be tested earlier in clinical trials. "These antibodies, I have worked with and developed for several years at my previous company, Cartela. I addition, the antibodies are human and therefore already adapted for human use. This means that we will save both time and money in our preclinical work and Xintela's ADC-based products can be tested earlier in clinical trials," says Xintela's CEO Evy Lundgren-Åkerlund.
As previously reported, Xintela has shown that mouse antibodies directed toward integrin a10b1 and linked to a cellular toxin had a killing effect on human gliobloma cells both in vitro and in vivo. With these findings, Xintela was able to demonstrate that treatment of glioblastoma cells with an Antibody-Drug-Conjugate (ADC) based on an integrin a10b1-antibody is a new, promising treatment concept for this aggressive brain tumor.
"It is advantageous for Xintela to have access to human antibodies that are well-characterized and have already shown promising results both on cells and in animal models. Primarily, we will develop the antibodies for the treatment of glioblastoma, but we will also evaluate the antibodies in other cancer forms to build a broader platform for cancer therapy and diagnostics," says Evy Lundgren-Åkerlund. Lund, Sweden, 29th of December 2017 Xintela AB (publ) Evy Lundgren-Åkerlund, CEO
Tel: 070-329 18 71
Email: [email protected]
Medicon Village
223 81 Lund
www.xintela.se
For investor relations and media questions, please contact:
Mårten Svanberg, Laika Consulting
Tel: 070-362 70 05
Email: [email protected]
www.laika.se
The following documents can be retrieved from beQuoted
Xintela Pressrelease 2017-12-29 English.pdf About Xintela
Xintela develops medical products for regenerative medicine and cancer based on its proprietary marker technology, XINMARK®. Xintela uses the technology to select and assure the quality of mesenchymal stem cells for the treatment of cartilage damage and osteoarthritis. In a study on horses, the company has shown that stem cells are safe to use and that they have a positive effect on the articular cartilage and the underlying bone after an injury. In addition, Xintela has developed an assay XACTTM for the quality control chondrocyte preprations in cell therapy of cartilage. XINMARK® is also used for the development of an antibody-based treatment (Antibody Drug Conjugate, ADC) against glioblastoma, the most common and aggressive form of brain tumors in adults. Positive preclinical results from cell studies and animal model have shown that the antibody has a killing effect on glioblastoma cells and thus has confirmed the concept. Xintela is listed on Nasdaq First North Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North is Erik Penser Bank AB, +46 8-463 80 00.
This information is such information that Xintela AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the above contact, for publication on the 29th of December 2017, at 08.50 CET.
If you want to open the text in your webbrowser
click here
______________________________________________________
This information was sent by beQuoted
If you want more information, please go to www.beQuoted.com
To change your subscription, please inform [email protected] beQuoted Press är en service till Dig som är intresserad av finansiell information. Med beQuoted Press underlättas företagens finansiella kommunikation till Dig och till nyhetsbyråer, aktieägare, placeringsrådgivare och andra intressenter på aktiemarknaden.
Vi hoppas att Du uppskattar denna service.
| 